# VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

> **NCT01830465** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Studio Linfomi** · enrollment: 45 (actual)

## Conditions studied

- Non Hodgkin's Follicular Lymphoma

## Interventions

- **DRUG:** Bortezomib (VELCADE)
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01830465
- **Lead sponsor:** Gruppo Italiano Studio Linfomi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-08
- **Final completion:** 2011-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2013-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01830465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01830465, "VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01830465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*